🚀 VC round data is live in beta, check it out!
Mycenax Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mycenax Biotech and similar public comparables like Savior Lifetec, Tonix Pharmaceuticals, Hyloris Pharmaceuticals, Whitehawk Therapeutics and more.
Mycenax Biotech Overview
About Mycenax Biotech
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company’s main operating region is located in Taiwan.
Founded
2001
HQ
Employees
309
Website
Financials (FY)
EV
$224M
Mycenax Biotech Financials
Mycenax Biotech reported last fiscal year revenue of $24M and negative EBITDA of ($4M).
In the same fiscal year, Mycenax Biotech generated ($6M) in gross profit, ($4M) in EBITDA losses, and had net loss of ($14M).
Revenue (LTM)
Mycenax Biotech P&L
In the most recent fiscal year, Mycenax Biotech reported revenue of $24M and EBITDA of ($4M).
Mycenax Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $24M | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($6M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (25%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (18%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (55%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($14M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (61%) | XXX | XXX | XXX |
| Net Debt | — | — | $22M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mycenax Biotech Stock Performance
Mycenax Biotech has current market cap of $197M, and enterprise value of $224M.
Market Cap Evolution
Mycenax Biotech's stock price is $0.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $224M | $197M | 0.5% | XXX | XXX | XXX | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMycenax Biotech Valuation Multiples
Mycenax Biotech trades at 9.5x EV/Revenue multiple, and (51.6x) EV/EBITDA.
EV / Revenue (LTM)
Mycenax Biotech Financial Valuation Multiples
As of April 19, 2026, Mycenax Biotech has market cap of $197M and EV of $224M.
Equity research analysts estimate Mycenax Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mycenax Biotech has a P/E ratio of (13.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $197M | XXX | $197M | XXX | XXX | XXX |
| EV (current) | $224M | XXX | $224M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (51.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (17.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (38.7x) | XXX | XXX | XXX |
| P/E | — | XXX | (13.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (55.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mycenax Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mycenax Biotech Margins & Growth Rates
Mycenax Biotech's revenue in the last fiscal year grew by 36%.
Mycenax Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Mycenax Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 36% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (18%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (0%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mycenax Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mycenax Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Savior Lifetec | XXX | XXX | XXX | XXX | XXX | XXX |
| Tonix Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Hyloris Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Whitehawk Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Karyopharm Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mycenax Biotech M&A Activity
Mycenax Biotech acquired XXX companies to date.
Last acquisition by Mycenax Biotech was on XXXXXXXX, XXXXX. Mycenax Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mycenax Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMycenax Biotech Investment Activity
Mycenax Biotech invested in XXX companies to date.
Mycenax Biotech made its latest investment on XXXXXXXX, XXXXX. Mycenax Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mycenax Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mycenax Biotech
| When was Mycenax Biotech founded? | Mycenax Biotech was founded in 2001. |
| Where is Mycenax Biotech headquartered? | Mycenax Biotech is headquartered in Taiwan. |
| How many employees does Mycenax Biotech have? | As of today, Mycenax Biotech has over 309 employees. |
| Is Mycenax Biotech publicly listed? | Yes, Mycenax Biotech is a public company listed on Taipei Exchange. |
| What is the stock symbol of Mycenax Biotech? | Mycenax Biotech trades under 4726 ticker. |
| When did Mycenax Biotech go public? | Mycenax Biotech went public in 2013. |
| Who are competitors of Mycenax Biotech? | Mycenax Biotech main competitors are Savior Lifetec, Tonix Pharmaceuticals, Hyloris Pharmaceuticals, Whitehawk Therapeutics. |
| What is the current market cap of Mycenax Biotech? | Mycenax Biotech's current market cap is $197M. |
| What is the current revenue of Mycenax Biotech? | Mycenax Biotech's last fiscal year revenue is $24M. |
| What is the current revenue growth of Mycenax Biotech? | Mycenax Biotech revenue growth (vs. last FY) is 36%. |
| What is the current EV/Revenue multiple of Mycenax Biotech? | Current revenue multiple of Mycenax Biotech is 9.5x. |
| Is Mycenax Biotech profitable? | No, Mycenax Biotech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.